114 results about "Urolithin" patented technology

Methods for preparing a salt of urolithin A and, in turn, urolithin A. Combining in an alkaline aqueous solution a copper-containing catalyst, 2-bromo-5-hydroxybenzoic acid, and resorcinol produces a salt of urolithin A. Urolithin A has been prepared by protonating a salt of the compound.

The invention relates to compositions comprising urolithins with active agents, particularly compositions comprising urolithins and one or more ginseng-derived compounds or a ginseng extract; and / or one of more notoginseng-derived compounds or a notoginseng extract. The invention also relates to uses of such compositions, for use for the treatment or prevention of diseases, disorders and conditions, and for non-therapeutic uses.

Provided are compositions comprising compounds or precursors to compounds which may be used for a variety of therapeutic applications including, for example, treating and / or preventing a disease or disorder related to reduced or inadequate mitochondrial activity, including aging or stress, diabetes, obesity, and neurodegenerative diseases. The compounds relate generally to urolithins and precursors thereof, including but not limited to ellagitannins and urolithin A. In certain embodiments the compositions are presented in or as food products or nutritional supplements. These same compounds and compositions can also be used advantageously in generally healthy individuals to increase or maintain metabolic rate, decrease percent body fat, increase or maintain muscle mass, manage body weight, improve or maintain mental performance (including memory), improve or maintain muscle performance, improve or maintain mood, and manage stress.

The invention relates to composition of urolithins comprising urolithins and pectin and formulations of urolithins, specifically chewable formulations, comprising urolithins and a gelling agent. The invention further comprises compositions and chewable formulations comprising urolithins in combination with other active ingredients and processes for the preparation of such compositions and formulations. The invention further comprises methods of using such compositions and formulations in the treatment of conditions and diseases and for the promotion of health and performance, such in the improving muscle function.

A nutraceutical composition, consisting of Nicotinamide Mononucleotide in a range 250-1000 mg, Spermidine in a range 0.5-10 mg, Rhodiola Rosea in a range 200-600 mg, Cacao in a range 1000-10,000 mg, L-Theanine in a range 50-200 mg, Glucosamine in a range 500-3000 mg, and Hyaluronic acid in a range 50-240 mg, or consisting of Epigallocatechin-3-gallate in a range 100-500 mg, Quercetin in a range 250-1000 mg, Resveratrol in a range 150-1000 mg, Sulforaphane in a range 1-50 mg, and Calcium Alphaketoglutarate in a range 300-2000 mg, or consisting of Microdose Lithium in a range 1-5 mg, Trimethylglycine in a range 500-2000 mg, Glutathione in a range 250-1000 mg, Fisetin in a range 100-1000 mg, Urolithin A in a range 250-2000 mg, Sodium Butyrate in a range 100-3000 mg, Berberine in a range 500-1500 mg, Apigenin in a range 50-500 mg, Cinnamon in a range 1000-6000 mg, and Malate in a range 1000-6000 mg.

The invention belongs to the technical field of health care products or daily chemical products, and particularly relates to a composition with anti-wrinkle, firming, whitening and brightening effects and application. The composition is prepared from the following components in parts by weight: 72 to 180 parts of fisetin, 120 to 180 parts of urolithin A and 5 to 15 parts of ergothioneine. Through precise component compounding, the synergistic interaction among fisetin, urolithin A and ergothioneine is brought into full play, the skin care composition integrating anti-wrinkle, firming, whitening and brightening functions is successfully developed, and the natural components of the skin care composition ensure the use safety of the product, so that the skin care composition has a good application prospect. The requirements of consumers on efficient skin care are effectively met.

The invention relates to the technical field of food engineering, and discloses pediococcus acidilactici, a microbial agent containing the pediococcus acidilactici, application of the microbial agent, sorghum fermented food and a preparation method of the sorghum fermented food. The preservation number of the pediococcus acidilactici is GDMCC (China General Microbiological Culture Collection Center) No.65676, and the pediococcus acidilactici can be used for preparing the pediococcus acidilactici. The microbial agent contains pediococcus acidilactici and auxiliary bacteria. According to the sorghum fermented food obtained through fermentation treatment of the fungicide, antinutritional factors such as tannin in sorghum can be converted into urolithin, hydrolysis of protein, fat and starch can be promoted, the utilization rate of the sorghum is increased, the quality and flavor of fermented products are improved, the fermentation period is shortened, the shelf life is prolonged, and high economic benefits are achieved.

A method of improving and / or enhancing at least one of bone mineralization, bone strength, bone mass, and bone mineral density in an individual in need thereof, the method comprising administering to the individual a composition comprising one or more anabolic amino acids, and the composition further comprising one or more autophagy-inducing compounds. In one embodiment, the one or more autophagy-inducing compounds are selected from the group consisting of thymol, carvacrol, spermidine, urolithin (e.g., Urolithin A, B or D), rapamycin, Torin1, valproic acid, polyphenols (e.g., resveratrol), caffeine, metformin, 5′ AMP-activated protein kinase (AMPK) activators, L-type calcium channel inhibitors, ketones (e.g. beta-hydroxybutyrate, ketone salts, or ketone ester derivatives), 4,4′-dimethoxychalcone and mixtures thereof.

The invention belongs to the field of microbial fermentation, and particularly relates to a culture medium for improving the efficiency of converting ellagic acid into urolithin A by lactobacillus mucus FUA033 and application of the culture medium. On the basis of a fermentation technology, under the same fermentation condition, the efficiency of converting ellagic acid to generate urolithin A by fermenting lactobacillus mucus FUA033 is improved by 21.13% and reaches 75.21% by optimizing a culture medium. The lactobacillus mucilaginosus FUA033 provides a technical support for preparing urolithin A through industrial green fermentation of the lactobacillus mucilaginosus FUA033 and developing fermented food rich in urolithin A, and has a good application prospect.

The invention belongs to the field of biological medicine, and particularly relates to application of urolithin D in preparation of medicine for relieving hyperuricemia. It is found for the first time that the urolithin D can significantly reduce the level of serum uric acid, improve the expression disorder of a kidney urate transporter, efficiently relieve or treat hyperuricemia and related diseases thereof, and relieve kidney injury and fibrosis; and the compound can be used for preparing medicines for treating hyperuricemia and related diseases, is low in cost and good in safety, and has a wide application prospect.

The present invention discloses compositions of Punica granatum whole spectrum extract (PWSE) extract comprising Urolithin A in the range of 0.2% - 10%, for improving general health, overall wellbeing and longevity by preventing age related disorders. The invention further discloses compositions comprising Punica granatum whole spectrum extract enriched with Punicagalins, Ellagic acid and Urolethin A. The invention additionally discloses a process for preparation of Punica granatum whole spectrum extract selectively enriched to comprise Punicagalins, Ellagic acid and Urolethin A.

The present invention relates to a combination of urolithin and immunotherapy treatments, in particular a combination of urolithin and a therapeutic agent, in particular a combination of urolithin and immunotherapy treatments, such as a PD-1 antagonist, and an immune checkpoint blocking therapy. The invention also relates to pharmaceutical compositions comprising said combination, processes for the preparation of said pharmaceutical compositions and methods of using said compositions in the treatment of disease. In one embodiment, the immune checkpoint blocking therapy is selected from the group consisting of an anti-PD-1 antibody, an anti-PD-L1 antibody, an anti-CTLA4 antibody, or a fusion protein.

The invention belongs to the technical field of pharmacy, and particularly relates to application of urolithin A in treating multiple organ injuries caused by sepsis. Experiments prove that the urolithin A can significantly reduce the apoptosis rate of bone marrow-derived macrophages, and can effectively relieve multi-organ injury caused by sepsis by regulating three key paths including oxidative stress, cell apoptosis and necrotic apoptosis. The application provides solid experimental basis and theoretical support for development of urolithin A as a sepsis treatment drug, and has important conversion value and clinical application prospect in the critical disease medical field.

Methylthioninium salt-containing compositions can include a methylthioninium salt and a second mitochondria-enhancing compound selected from urolithin A having a methylthioninium salt to urolithin A weight ratio from about 1:600 to about 1:4, pyrroloquinoline quinone having a methylthioninium salt to pyrroloquinoline quinone weight ratio from about 1:20 to about 50:1, tesofensine having a methylthioninium salt to tesofensine weight ratio from about 1:2 to about 100:1, or a combination thereof.

The present application relates to the technical field of extraction and utilization of chemical substances in walnut green husk, and particularly relates to a production process of urolithin A, in particular to the following steps: obtaining walnut green husk; preparing a fermentation substrate: crushing the walnut green husk into a slurry and adding a stabilizing solution, stirring uniformly and then performing ultrasonic treatment to obtain the fermentation substrate, the stabilizing solution being an aqueous solution of a compound of mercapto-beta-cyclodextrin and chitosan; first fermentation: inoculating microbial liquid A for anaerobic fermentation, then filtering and collecting the filtrate, the microbial liquid A being obtained by inoculating Bacillus velezensis and Bacillus coagulans into culture medium A respectively for activation by shaking culture and then mixing; second fermentation: inoculating microbial liquid B into the filtrate for anaerobic fermentation again, the microbial liquid B being obtained by inoculating Enterococcus faecalis into culture medium B for culture; and extraction, wherein the present application significantly improves the yield and conversion rate of urolithin A by adding the stabilizing solution to the walnut green husk and performing two-stage fermentation, and is safe, environmentally friendly and industrialized.

The invention discloses a synergistic anti-oxidation urolithin A composition and application thereof in improving the ovarian function direction, and relates to the technical field of biological medicine, and the active ingredients of the composition comprise 10-100 parts of urolithin A and 6-40 parts of coenzyme Q10. According to the composition disclosed by the invention, the used raw materials are food-grade raw materials such as urolithin A and coenzyme Q10, and the urolithin A and the coenzyme Q10 are matched within a certain range, so that a good synergistic interaction effect can be achieved, and the composition has a good antioxidant effect; meanwhile, the composition also has the effects of effectively improving the ovarian reserve function, regulating the hormone level, improving menstruation, skin, emotion, sleep and the like at a low dosage level, and is effective and safe.

The invention relates to composition of urolithins comprising urolithins and pectin and formulations of urolithins, specifically chewable formulations, comprising urolithins and a gelling agent. The invention further comprises compositions and chewable formulations comprising urolithins in combination with other active ingredients and processes for the preparation of such compositions and formulations. The invention further comprises methods of using such compositions and formulations in the treatment of conditions and diseases and for the promotion of health and performance, such in the improving muscle function.

This invention relates to the field of traditional Chinese medicine analysis, and particularly to a method for determining the content of multiple components in Terminalia chebula and constructing its characteristic fingerprint spectrum. The method provided by this invention can simultaneously determine chebulin, gallic acid, 4-galloshikimic acid, 5-galloshikimic acid, punicalin (punicalin A&B), corilagin, 1,3,6-tri-O-galloyl-β-D-glucose, chebulin, urolithin M5, chebulin tannic acid, chebulin-lintannic acid, and ellagic acid in Terminalia chebula. It exhibits high sensitivity, good precision, repeatability, and stability, and can be used to detect the tannin content in the extract at each step of the tannin extraction process, as well as for related detection in the study and quality evaluation of tannin components in Terminalia chebula. It can also be used to construct the characteristic fingerprint spectrum of Terminalia chebula. This method can also be used for determining the content of tannin compounds and constructing their characteristic fingerprint spectrum in Terminalia chebula, which contains similar tannin compounds to Terminalia chebula.

The invention relates to the technical field of health-care products, and particularly discloses a roselle-containing composition and a preparation method thereof, and the roselle-containing composition comprises the following components: a roselle extract, a cocoa extract, coating protein, a fermentation compound and auxiliary materials; the added roselle extract is subjected to multi-step pretreatment, the extraction rate and stability of active ingredients are improved, and the polarity of the roselle extract can be adjusted by adopting a composite solvent for extraction, so that the bioavailability is improved; the added cocoa extract can reduce oxidation of anthocyanin, and the cocoa extract and the roselle extract are synergistically used for reducing blood fat by inhibiting lipase activity and adjusting cholesterol; the fermentation compound can generate urolithin A, pueraria peptide and perillyl alcohol to further assist in reducing blood fat, and the coating protein improves the stability and absorption efficiency of the roselle extract; the auxiliary materials can improve the bioavailability of the active components of the raw materials, and the prepared composition has the effects of inhibiting appetite, promoting lipolysis, inhibiting fat absorption and reducing blood fat through synergistic effects of all the components.

This invention provides urolithin A cocrystals, their preparation methods, compositions, and applications. Specifically, this invention provides a urolithin A cocrystal with high bioavailability, wherein the urolithin A cocrystal is selected from the group consisting of: urolithin A-proline cocrystals, urolithin A-carnitine cocrystals, urolithin A-nicotinamide cocrystals, or urolithin A-creatine cocrystals. Compared to urolithin itself, the urolithin A cocrystals of this invention exhibit high stability, a significantly lower melting point, and significantly improved solubility and bioavailability. Furthermore, the preparation method is simple, easy to control, and has good reproducibility, allowing for stable acquisition of the target cocrystal. The composition containing the cocrystal, prepared by grinding, has high yield, low cost, and is suitable for large-scale production.

The invention relates to the technical field of drug delivery systems, and provides electrostatic spinning microspheres of ellagic acid and urolithin and a preparation method of the electrostatic spinning microspheres. According to the preparation method disclosed by the invention, the nano-microspheres prepared from alginate and chitosan are successfully prepared by utilizing an electrostatic spinning technology, and ellagic acid and metabolin thereof, namely urolithin, are effectively encapsulated, so that a guarantee is provided for efficient delivery of medicines. The prepared electrostatic spinning microspheres are uniform in particle size distribution, the packaging efficiency reaches 60-88%, and FTIR and TGA prove that the medicine is successfully embedded and has good thermal stability. Compared with free drugs, the drug-loaded microspheres still show excellent antioxidant activity, and the DPPH and ABTS removal activity before and after EA and Uro C are encapsulated is the highest. An in-vitro digestion experiment shows that compared with a free drug, the drug loss of the microsphere in stomach and intestine stages is reduced by 32%-69%, the drug can be protected to smoothly reach the colon to play a role, and the bioavailability of the drug is greatly improved.

The invention belongs to the technical field of medicines, and particularly relates to application of urolithin A and beta-nicotinamide mononucleotide in preparation of a medicine for treating diabetes. The invention finds that when the urolithin A and the beta-nicotinamide mononucleotide are independently used, the hypoglycemic effect on diabetic mice cannot be realized, and when the urolithin A and the beta-nicotinamide mononucleotide are jointly used, the symptoms of diabetes and insulin resistance caused by high fat diet can be remarkably improved; the glucose tolerance and the insulin tolerance are improved; meanwhile, the content of low-density lipoprotein and cholesterol in a mouse body is reduced, so that the risk of thrombus occurrence is reduced; in addition, combined medication can significantly reduce liver cell lipid accumulation and improve mitochondrial morphological abnormality. The invention provides a brand new technical scheme and experimental basis for treating diabetes caused by high fat diet and relieving insulin resistance, and has important medical application value.

The invention belongs to the technical field of food microorganisms and fermentation engineering, and particularly relates to lactobacillus plantarum and application of the lactobacillus plantarum in preparation of urolithin A-rich plant-based yogurt. Specifically, the lactobacillus plantarum SFFI 76 with the capacity of efficiently converting punicalagin into urolithin A is successfully screened and obtained, the conversion rate of urolithin A of the strain in a punicalagin-MRS culture medium is as high as 6.59%, and therefore when the lactobacillus plantarum SFFI 76 is applied to the preparation process of pomegranate plant-based yoghurt, the pomegranate plant-based yoghurt rich in urolithin A and rich in urolithin A can be successfully prepared. Meanwhile, the pomegranate plant-based yoghurt has good physicochemical properties, antioxidant activity and flavor, so that the pomegranate plant-based yoghurt has good practical application value.

The invention relates to the technical field of organic synthesis, in particular to a synthesis method and application of a dibenzo-alpha-pyrone compound. The synthesis method comprises the following steps: taking a dipropiophenone compound as a raw material, using an oxidizing agent, lewis acid and an oxidation catalyst, and reacting in an organic solvent at room temperature. According to the synthesis method disclosed by the invention, the dibenzo-alpha-pyrone compound is prepared by taking the easily available benzophenone compound as a raw material through Baeyer-Villiger oxidation and Scholl oxidative coupling by a one-pot method, the reaction is simple and convenient, the condition is mild, and a more efficient and green method is provided for preparing bioactive substances such as urolithin a-c.

The invention discloses an engineering strain for producing urolithin A and application of the engineering strain. The engineering strain contains a tannin acyl hydrolase gene tah, an esterase gene lip, a gallic acid decarboxylase gene gdo and a dopamine dehydroxylase gene ascd. The four artificially synthesized genes are jointly constructed on an escherichia coli expression vector, so that a brand-new vector containing four co-expression genes is constructed, then the brand-new vector is transferred into a chassis strain cell to realize co-expression of the four genes, and four enzymes expressed in the cell all have activity; and the obtained heavy engineering strain can stably convert the extracellular added ellagic tannin into the urolithin A, so that the whole-cell catalysis process of producing the urolithin A by taking the ellagic tannin as a substrate is realized.

Described is a composition comprising: (a) a compound of formula (I), or a salt, prodrug, metabolite or derivative thereof; (I) wherein: A, B, C, D, W, X, Y and Z are each independently selected from H and OH; and (b) one of more agents selected from agents for improving skin health, wherein the agents for improving skin health are selected from one or more of the following: (i) one or more ceramides, for example, one or more phytoceramides; (ii) a carotenoid, for example, lycopene and / or lutein; c. zinc or a salt thereof; d. astaxanthin; and optionally e. L-lysine; f. one or more NAD boosters, for example, nicotinamide and / or co-enzyme Q10; g. eggshell membrane or an extract thereof; and / or h. biotin, or a derivative thereof.

Disclosed are compounds, compositions, and methods useful for inhibiting ferroptosis in a subject in need thereof.

The invention discloses a preparation method of urolithin A. The method comprises the following steps: S1, adding 2, 7-dichloro-9-fluorenone, L-proline, tert-butyl hydroperoxide, alkali and copper salt into a reaction solvent, stirring, and heating for reaction to obtain an intermediate; s2, cooling: dropwise adding a sulfuric acid aqueous solution into the intermediate, after dropwise adding is completed, performing heating heat treatment, after heat treatment is completed, cooling, performing vacuum filtration, leaching a filter cake with water, and performing vacuum drying to obtain urolithin A. The preparation method of urolithin A provided by the invention effectively reduces the synthesis cost, avoids the use of dangerous and toxic reagents, effectively reduces the generation of industrial three wastes, and has the advantages of simple process, convenient operation, cheap and easily available raw materials, high yield, and facilitation of large-scale industrial production.

The invention relates to compositions comprising urolithins with active agents, particularly compositions comprising urolithins and agents which promote brain health and / or immune health. The invention also relates to such compositions, for use for the treatment or prevention of diseases, disorders and conditions, and for use in non-therapeutic treatments. Example of agents which promote brain health include brain protective agents (for example phosphatidylserine, phosphatidylcholine and / or choline), agents that enhance neurotransmission (for example a nootropic, for example ergothioneine, huperzine, aGPC, taurine and / or L-theanine), agents that promote neurogenesis (for example selenium); and brain essential nutrients (example Vitamin B6, B9, B12, magnesium salts, folic acid and / or L-methylfolate). Examples of agent which promote immune health include quercetin, Elderberry or an extract thereof; a selenium salt; and / or a zinc salt.